Catabasis Pharmaceuticals Inc (NASDAQ:CATB) has earned a consensus rating of “Buy” from the seven ratings firms that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average twelve-month price target among brokers that have covered the stock in the last year is $4.82.

CATB has been the subject of several research reports. Citigroup upgraded shares of Catabasis Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $3.00 target price for the company in a report on Monday, November 20th. Zacks Investment Research downgraded shares of Catabasis Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Monday, October 16th. Oppenheimer raised their price target on shares of Catabasis Pharmaceuticals from $4.00 to $7.00 and gave the company an “outperform” rating in a research report on Thursday, October 5th. CIBC reissued an “outperform” rating and issued a $7.00 price target (up previously from $4.00) on shares of Catabasis Pharmaceuticals in a research report on Thursday, October 5th. Finally, Cowen reissued a “market perform” rating and issued a $2.00 price target on shares of Catabasis Pharmaceuticals in a research report on Friday, October 6th.

Hedge funds have recently modified their holdings of the business. Renaissance Technologies LLC purchased a new position in Catabasis Pharmaceuticals in the 1st quarter valued at approximately $106,000. Oppenheimer & Co. Inc. boosted its position in Catabasis Pharmaceuticals by 33.3% in the 2nd quarter. Oppenheimer & Co. Inc. now owns 120,000 shares of the biotechnology company’s stock valued at $169,000 after buying an additional 30,000 shares during the period. Virtu KCG Holdings LLC purchased a new position in Catabasis Pharmaceuticals in the 2nd quarter valued at approximately $271,000. Finally, Wedbush Securities Inc. boosted its position in Catabasis Pharmaceuticals by 2,368.6% in the 3rd quarter. Wedbush Securities Inc. now owns 251,802 shares of the biotechnology company’s stock valued at $534,000 after buying an additional 241,602 shares during the period. 33.14% of the stock is owned by institutional investors.

Catabasis Pharmaceuticals (CATB) traded up $0.03 during trading on Thursday, reaching $1.79. Catabasis Pharmaceuticals has a one year low of $1.08 and a one year high of $5.51.

Catabasis Pharmaceuticals (NASDAQ:CATB) last posted its earnings results on Thursday, November 9th. The biotechnology company reported ($0.31) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.33) by $0.02. The company had revenue of $0.25 million during the quarter. analysts anticipate that Catabasis Pharmaceuticals will post -1.39 EPS for the current year.

TRADEMARK VIOLATION WARNING: “Brokerages Set Catabasis Pharmaceuticals Inc (CATB) Target Price at $4.82” was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The legal version of this article can be read at https://www.watchlistnews.com/brokerages-set-catabasis-pharmaceuticals-inc-catb-target-price-at-4-82/1756436.html.

Catabasis Pharmaceuticals Company Profile

Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.

Analyst Recommendations for Catabasis Pharmaceuticals (NASDAQ:CATB)

Receive News & Ratings for Catabasis Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.